Analysis of Treatment for Eye Cancer Based on Existing Materials
DOI:
https://doi.org/10.54097/sjdh9g64Keywords:
Eye cancer, Surgical excisions, Chemotherapy, Immune Checkpoint Inhibitor Therapy.Abstract
With the improvement of screening mechanisms for eye diseases and the popularization of cancer screening, more and more people discover that they have different types and degrees of eye cancers. These cancers can affect the skin of their eyes, may also make their vision decreased, and may even deprive their eyeballs. Besides, these diseases will affect patients’ physical and mental health. Therefor patients want to find the most appropriate treatment to manage the disease. However, some treatments are may not so effective or suitable for each individual. Based on the existing literature, canonical analysis, clinical trial analysis and content integration were used to analyze the three effective and popular methods of treating ocular cancers. Studies have found that Surgical excisions, Chemotherapy, Immune Checkpoint Inhibitor therapy are effective in the treatment of eye cancers (squamous cell carcinoma of the eyelids, basal cell carcinoma of the eyelids, retinoblastoma, metastatic melanoma of eye and orbit), although some treatments do not have the most effective treatment for some cancers.
Downloads
References
Lee, P. P., Feldman, Z. W., Ostermann, J., Brown, D. S., & Sloan, F. A. (2003). Longitudinal prevalence of major eye diseases. Archives of Ophthalmology, 121 (9), 1303 - 1310.
Zou, H. D. (2017). The problems and challenges in the current eye health management in China. [Zhonghua yan ke za Zhi] Chinese Journal of Ophthalmology, 53 (7), 481 - 483.
Baş, Z., Sharpe, J., Yaghy, A., Zhang, Q., Shields, C. L., Hyman, L., & IRIS Registry Analytic Center Consortium. (2023). Prevalence of and Associated Factors for Eyelid Cancer in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology Science, 3 (1), 100227.
Wong, C. S. M., Strange, R. C., & Lear, J. T. (2003). Basal cell carcinoma. Bmj, 327 (7418), 794 - 798.
Perlman, G. S., & Hornblass, A. (1976). Basal cell carcinoma of the eyelids: a review of patients treated by surgical excision. Ophthalmic Surgery, Lasers and Imaging Retina, 7 (4), 23 - 27.
Mohs, F. E. (1986). Micrographic surgery for the microscopically controlled excision of eyelid cancers. Archives of Ophthalmology, 104 (6), 901 - 909.
Payne, J. W., Duke, J. R., Butner, R., & Eifrig, D. E. (1969). Basal cell carcinoma of the eyelids: a long-term follow-up study. Archives of ophthalmology, 81 (4), 553 - 558.
Narang, S., Mashayekhi, A., Rudich, D., & Shields, C. L. (2012). Predictors of long‐term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clinical & experimental ophthalmology, 40 (7), 736 - 742.
Schwartz, R. A., & Schwartz, R. A. (1988). Squamous cell carcinoma. Skin cancer: recognition and management, 36 - 47.
Reifler, D. M., & Hornblass, A. (1986). Squamous cell carcinoma of the eyelid. Survey of ophthalmology, 30 (6), 349 - 365.
Dimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., & Gallie, B. L. (2015). Retinoblastoma. Nature reviews Disease primers, 1 (1), 1 - 23.
Mitchison, D. A. (1979). Basic mechanisms of chemotherapy. Chest, 76 (6), 771 - 780.
Shields, C. L., Manjandavida, F. P., Lally, S. E., Pieretti, G., Arepalli, S. A., Caywood, E. H., ... & Shields, J. A. (2014). Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology, 121 (7), 1453 - 1460.
Marr, B. P., Dunkel, I. J., Linker, A., & Abramson, D. H. (2012). Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity. British journal of ophthalmology, 96 (6), 881 - 883.
Smith, S. J., Smith, B. D., & Mohney, B. G. (2014). Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. British Journal of Ophthalmology, 98 (3), 292 - 297.
Wheatley, K., Ives, N., Hancock, B., Gore, M., Eggermont, A., & Suciu, S. (2003). Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer treatment reviews, 29 (4), 241 - 252.
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018). Immune checkpoint blockade therapy. Journal of Allergy and Clinical Immunology, 142 (5), 1403 - 1414.
Hong, B. Y. B., Ford, J. R., Glitza, I. C., Cabala, C. A. T., Tetzlaff, M., Prieto, V. G., ... & Esmaeli, B. (2021). Immune checkpoint inhibitor therapy as an eye-preserving treatment for locally advanced conjunctival melanoma. Ophthalmic plastic and reconstructive surgery, 37 (1), e9.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
